Business
Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its correlation with amyloid beta and slowing cognitive and functional
About this update from Biogen Inc.
[{"type":"text","content":"Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its correlation with amyloid beta and slowing cognitive and functional decline.Additional phase 3b late breaker data will shed light on clinical decline and amyloid beta plaque levels after patients stopped treatment.With data from the largest clinical trial dataset in early Alzheimer’s disease, Biogen contributes 11 presentations to CTAD, supporting robust scientific insights and dialogue. CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present a variety of new data from its Alzheimer’s disease product portfolio and clinical development pipeline at the upcoming annual Clinical Trials on Alzheimer’s Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts. Biogen’s contributions to the conference are driven in part by analyses from the largest clinical trial dataset in early Alzheimer’s disease research. This includes over 3,000 patients in Phase 3 trials and approximately 1,700 patients in the ADUHELM (aducanumab-avwa) redosing trial, EMBARK. A late breaking presentation will highlight important new data from over 7,000 plasma samples from the ADUHELM Phase 3 trials that, for the first time, examines the effect of ADUHELM on plasma phosphorylated tau181 (p-Tau181) and its correlation to amyloid beta plaques and disease progression, as measured by clinical decline endpoints, in patients with early Alzheimer’s disease. The accumulation of amyloid beta plaques and tangles of tau proteins in brain cells are the two defining pathologies of Alzheimer’s disease. “We collected an unprecedented sample size—approximately 7,000 plasma samples from more than 1,800 patients—to provide robust answers to questions about the correlation between plasma pTau reduction, amyloid beta plaque levels and clinical decline in Alzheimer’s disease. We are eager to engage the scientific community with the findings from this comprehensive dataset,” said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. “The clinical insights we can derive from our data at CTAD are meaningful. These can help inform clinician, patient and caregiver choice and future treatment decisions, as well as advance the field’s understanding of this devastating disease.” The data will be discussed at the virtual oral pres...